The circadian production of melatonin by the pineal gland during the night provides an inhibitory signal to tissue-isolated steroid receptor SR+ and -MCF-7 human breast cancer xenografts in female nude rats. A pivotal mechanism for melatonin's anticancer effects in vivo involves a melatonin receptor-mediated inhibition of linoleic acid (LA) uptake and its metabolism to mitogenically active 13-hydroxyoctadecadienoic acid (13-HODE). Exposure of (SR-) xenograft-bearing rats to increasing intensities of polychromatic white light at night suppresses melatonin while increasing tumor growth rates, DNA content, [3H]thymidine incorporation into DNA, LA uptake, 13-HODE formation, cAMP levels and ERK1/2 activation a dose-dependent manner. Similar effects occur in SR-human breast cancer xenografts perfused in situ with melatonindepleted blood from healthy female subjects after their exposure to a single bright intensity (2800 lux) of polychromatic light at night. Additionally, SR-human breast cancer xenografts exhibit robust circadian rhythms of LA uptake, 13-HODE formation and proliferative activity. Exposure of xenograft-bearing rats to dim light at night results in the complete elimination of these rhythms which culminates in unfettered, high rates of tumor metabolism and growth. The organization of tumor metabolism and growth within circadian time structure by the oncostatic melatonin signal helps create a balance between the cancer and its host that is disrupted by host exposure to light at night. This biological mechanism may partially explain the higher risk of breast and other cancers in women working rotating night shifts and possibly others who also experience prolonged exposure to light at night.
Introduction
The rhythmic, circadian organization of human physiology and metabolism that is so characteristic of normal cells and tissues also persists during the earlier phases of oncogenesis in malignant neoplasms derived from these same structures. The temporal organization of the multitude of processes governing cancer initiation, growth, progression, and invasion/metastasis are regulated by host circadian rhythmic outputs from the central circadian pacemaker in the suprachiasmatic nuclei (SCN). 1 It is important to note that in addition to the central circadian system, peripheral clock mechanisms may be involved in the regulation of cell proliferation as well. 2 A major question in circadian cancer biology is how the central circadian pacemaker (ie, SCN) transmits biological timing information to diverse and remote peripheral locations of cancer cells within their tumor microenvironment to temporally organize cell proliferation, metabolism, and tumor growth on a daily basis. Also, how does the central circadian timing system influence the regulatory interactions between signal transduction, intermediary metabolism, and cell proliferation in tumors? In this article, we will discuss some recently published and unpublished work from our own laboratory regarding the role of the nocturnal circadian melatonin signal and the consequences of its disruption by light at night (in both female rats and women), in the regulation of signal transduction, metabolism, growth, and proliferative activity of tissue-isolated human breast cancer xenografts in vivo to provide some preliminary ans wers to these questions.
Melatonin Suppression of Cancer Growth Activity In Vivo via Melatonin Receptor-Mediated Inhibition of Tumor Signal Transduction and Metabolic Activity
A key pathway mediating melatonin's cancer inhibitory action on tumor growth in vivo involves the essential omega-6 polyunsaturated fatty acid (PUFA), linoleic acid (LA). 3, 4 As the most prevalent PUFA in the Western diet, LA levels greatly exceed those required to prevent essential FA deficiency (ie, 1% of total calories). 5 As a potent oncogenic stimulus for both murine and human tumorigenesis, LA exerts act ions on cancer cells that are diametrically opposed to virtually all the oncostatic actions of melatonin discovered thus far. LA's diverse oncogenic effects are related to its ability to upregulate the expression of genes and proteins involved in estrogen receptor (ERa) expression, cell cycle progression, G protein signaling, extracellular signal-regulated kinase (ERK)1/2 and PI3 kinase/Akt/mTOR growth cascades while downregulating intercellular communication. 3 In both tissue-isolated SR+ and SR-human breast cancer xenografts perfused in situ, physiological melatonin (1 nM) suppresses tumor cAMP formation, leading to a suppression of LA uptake and its metabolism to the mitogenic signaling molecule 13-hydroxyoctadecadienoic acid (13-HODE). Downregulation of LA uptake and metabolism reduces the activation of the epidermal growth factor receptor (EGF)/MEK/ERK1/2 pathway, which is important in cell proliferation and survival, culminating in tumor growth inhibition. 6 Similarly, perfusion of these xenografts in situ with melatonin also red uces the activation of Akt, also important for cell survival and proliferation, presumably via melatonin-induced inhibition of LA uptake and metabolism (unpublished data). The coperfusion of breast cancer xenografts with melatonin plus the nonselective MT 1 and MT 2 melatonin receptor antagonist S20928 prevents all these melatonin-induced effects. On the other hand, the selective MT 2 melatonin receptor antagonist 4P-PDOT fails to prevent these effects, indicating that melatonin-induced inhibition of tumor signal transduction, LA uptake, 13-HODE formation, and proliferative activity is exclusively mediated via the MT 1 melatonin receptor. 7
Nocturnal Melatonin Suppression by Light at Night and Human Breast Cancer Risk
Recently, we assessed the dose-response effects of light exposure during darkness on growth, LA uptake/metabolism to 13-HODE, and signal transduction activity in tissue-isolated SR-MCF-7 human breast cancer xenografts in nude female rats. 6 Groups of rats were each exposed to different, increasing intensities (total dark, 0.02. 0.05, 0.06, 0.08, or 345 mW/cm 2 ) of white, fluorescent polychromatic light during the dark phase of an alternating 12-hour light/12-hour dark cycle beginning 2 weeks before tumor implantation and continuing thereafter until the end of the tumor growth experiment ( Figure  1 ). Following several weeks of exposure of rats to increasingly brighter light during the dark phase (from total darkness to bright light), there was a dose-dependent increase in the percentage suppression of peak nocturnal serum melatonin levels ( Figure 2A ). There was also an accompanying marked, dose-related increase in LA uptake, 13-HODE formation, DNA content, levels decreased. Dark-phase serum corticosterone and estradiol levels were unaffected by increasing light intensities. The light intensity-dependent suppression of nocturnal circulating melatonin titers translated to a light intensity-dependent stimulation of human breast cancer xenograft signal transduction activity, LA uptake/metabolism to 13-HODE, and growth/proliferative activity. A most interesting aspect of this study was that dim light at night (0.08 mW/cm 2 or 0.2 lux), which induced an approximately 65% suppression of the amplitude of the nocturnal melatonin signal in the blood, resulted in a stimulation of tumor growth, signal transduction, and metabolic activity that was nearly complete and equivalent to that observed in constant bright light-exposed tumor-bearing rats with complete melatonin suppression. This confirmed our previous findings on tumor growth and metabolism in tissue-isolated rat hepatoma 7288CTC in Buffalo rats exposed to either dim light at night or constant bright light. 3, 4 The stimulatory effects of dim light present during the entire night on rat hepatoma and human breast cancer xenograft growth were recently and independently corroborated with respect to the growth of DMBA-induced mammary carcinomas in female rats. 8 The risk of developing breast cancer is up to 5 times higher in industrialized nations than in less developed countries. Overall, nearly 50% of breast cancers cannot be accounted for by conventional risk factors. 9, 10 Westernized nations have increasingly become 24-hour per day societies, with greater numbers of people being exposed to more artificial light during the night both at home and particularly in the workplace. 11, 12 It has been postulated that light exposure at night may represent a unique risk factor for breast cancer in industrialized societies via its ability to suppress the nocturnal production of melatonin by the pineal gland. 9, 10 This hypothesis is based on studies showing that melatonin inhibits the development and growth of experimental models of breast cancer, whereas either surgical removal of the pineal gland or exposure to constant light stimulates mammary tumorigenesis in rodents. 3, 4 This postulate is further strengthened by recent epidemiological studies demonstrating that women and men working rotating night shifts have a significantly elevated risk of not only breast cancer, [13] [14] [15] but colorectal 17 and endometrial cancer 18 as well, whereas men are at higher risk for prostate cancer, 19 possibly because of their increased exposure to light at night.
Experimental studies from our laboratories have uncovered important new relationships between human breast cancer risk and circadian biology, the endogenous nocturnal melatonin signal, and its suppression by light at night. 6 The signal transduction, metabolic, and proliferative activities of human breast cancer tissue growing in nude rats, perfused in situ with blood collected during completely dark nights from premenopausal women (ie, high melatonin), is markedly reduced as compared with the case when the tissue is perfused with daytime blood (ie, low melatonin; Figures 3A  and 3B ). Subsequent exposure of human subjects to bright (2800 lux), polychromatic white fluorescent light during the night completely extinguishes the tumor inhibitory activity of their blood. That this effect was achieved via light-atnight-induced melatonin suppression is supported by the fact that addition of a physiological nocturnal concentration of melatonin (500 pM) to the low-melatonin blood collected from those who were light treated restored the tumor inhibitory activity observed in the melatonin-rich blood collected at night during total darkness ( Figure 3A and 3B ). Therefore, melatonin is the first soluble, nocturnal anticancer signal to be identified in humans that directly links the central circadian clock with some of the important mechanisms regulating breast carcinogenesis. These findings also provide the first definitive nexus between the exposure of healthy premenopausal female humans to bright, white light at night and the enhancement of human breast oncogenesis via circadian disruption (ie, suppression) of the nocturnal, oncostatic melatonin signal. The suppression of circadian melatonin production by ocular exposure to bright white light at night, leading to augmented nocturnal tumor uptake of dietary LA and its conversion to mitogenically active 13-HODE, can now be afforded serious consideration as a potentially new risk factor for human breast cancer. Indeed, subsequent epidemiological studies have confirmed that both premenopausal and postmenopausal women, in general, who have lower nocturnal levels of melatonin are at significantly greater risk for breast cancer than those with higher levels of melatonin at night. 20, 21 
Circadian Rhythms of Cancer FA Metabolism and Growth Activity and Their Disruption by Light at Night In Vivo
Initial work from our laboratory with the highly melatoninsensitive tissue-isolated Morris rat hepatoma 7288CTC revealed that this tumor exhibits prominent circadian rhythms in LA uptake and 13-HODE production. 3, 4 For example, tumor LA (and total FA) uptake and the formation of in the blood of tumor-bearing male Buffalo rats. On the other hand, during the mid-dark phase, tumor LA uptake and 13-HODE production plummet to undetectable levels coincident with peak circulating titers of melatonin. The rhythms of daytime elevation and nocturnal suppression of tumor LA uptake and metabolism are eliminated in animals lacking a nocturnal circadian melatonin signal because of removal of the pineal gland, resulting in high rates of LA uptake, metabolism to 13-HODE during both the light and dark phases, and consequently, significantly higher rates of tumor growth compared with sham-operated animals. These findings indicate that the circadian rhythms of LA uptake and metabolism to 13-HODE in tissue-isolated rat hepatoma 7288CTC under entrained light-dark conditions are not endogenous tumor rhythms but, rather, slave oscillations directly driven by the nocturnal circadian melatonin signal emanating from the pineal gland.
In more current work (unpublished), we have examined whether tissue-isolated SR-MCF-7 human breast cancer xenografts grown in female nude rats, like the rat hepatomas described above, also exhibit circadian rhythms in LA uptake, metabolism to 13-HODE, and proliferative activity and, if so, whether those rhythms would be disrupted by exposure of tumor-bearing rats to dim light (0.2 lux) at night. Figure 4 shows prominent oscillations in the tumor FA uptake and metabolism, with peak LA and TFA uptake and production of 13-HODE during the light phase 2 hours prior to lights off and a nadir in those parameters during the dark phase 2 hours before lights on. Similar fluctuations were observed in the proliferative activity of these human breast cancer xenografts with peak incorporation of [ 3 H]thymidine into DNA also during the light phase 2 hours prior to lights off and lowest thymidine incorporation during the dark phase 2 hours prior to lights on (Figure 4) . The high daytime and low nighttime levels of tumor proliferative activity, LA uptake, and metabolism to 13-HODE were 180° out of phase with the plasma melatonin rhythm in the host rats (data not shown). Exposure of tumor-bearing rats to dim light during the dark phase resulted in an almost complete suppression of the nocturnal circadian melatonin signal, as observed in previous studies, 6 and a complete elimination of the tumor rhythms of LA uptake and metabolism and proliferative activity (unpublished data not shown).
Taken together, these preliminary findings not only corroborate similar tumor growth rhythms in murine breast cancer 22 but demonstrate for the first time that tissue-isolated human breast cancer xenografts exhibit robust daily rhythms of FA uptake and metabolism and proliferative activity, indicating that tumor metabolism and growth is a very dynamic, homeokinetic process rather than a homeostatic one. That these rhythms are, in fact, circadian rhythms driven by the nocturnal circadian melatonin signal is supported by the findings that they are negated when nocturnal melatonin production is nearly totally suppressed by dim light exposure during the night ( Figure 5 ).
Conclusions
Based on the findings reviewed here in female rats and women, we propose that the nocturnal melatonin rhythm represents a critically important chronobiotic signal from the central circadian system, which not only directly inhibits human breast cancer signal transduction activity, mitogenic LA metabolism, and proliferation/growth but by virtue of its oncostatic properties, temporally organizes cancer metabolism and growth to help maintain the hostcancer balance. The inappropriate presence of light (of sufficient duration and intensity) during the night dysregulates the circadian organization of cancer growth and metabolism, and thus the host-cancer balance, through one type of central circadian disruption involving suppression of the circadian oncostatic melatonin signal. Disruption of tumor circadian organization shifts the host-cancer balance in favor of constantly upregulated tumor metabolism that fuels "runaway" cancer cell proliferation and survival. This may provide at least one plausible explanation for the higher risk of breast and other cancers observed in women working rotating night 
